Rare Disease Taskforce meets in London

Tomorrow, on March 3, 2016, in London, UK, a Workshop is held at EMA to discuss actions to reach agreement between the different stakeholders on appropriate small population studies. Under the roof of IRDiRC, a Task Force was founded to advance discussions on ways to optimise and improve commonly adopted approaches and to reach agreement between the different stakeholders on appropriate small population studies. The programme of the Task Force can be found here.

The IDeAl consortium will be strongly represented at the meeting with 10 (former) partners or members of advisory board:

Ralf-Dieter Hilgers (IDeAl; RWTH Aachen, Germany)
Paolo Baroldi (Vanda Pharmaceuticals, USA)
Frank Bretz (Novartis, Switzerland)
Carl-Fredrik Burman (Astra Zeneca; Chalmers University, Sweden)
Olivier Collignon (EMA, UK)
Mats Karlsson (Uppsala University, Sweden)
Franz König (Medical University Vienna, Austria)
Geert Molenberghs (KU Leuven, Belgium)
Gérard Nguyen (Rett Syndrome Europe, France)
Stephen Senn (Luxembourg Institute of Health, Luxembourg)

Together with the Scientific Secretariat, the Task Force is creating a draft document for debate on SPCT matters. In due time, this will be open for the community at large for comments and suggestions. This draft is available for comments and consultation on the Task Force’s Website.